SEC Filing Summary: Galena Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Galena Biopharma, Inc. on October 31, 2016, reporting events occurring on October 26, 2016. The filing addresses a material modification to the rights of security holders regarding a reverse stock split.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: The Board of Directors approved a one-for-twenty (1:20) reverse stock split of outstanding common stock.
- Authorization: The split was authorized by stockholders on October 21, 2016.
- Effective Date: The split becomes effective on November 11, 2016.
- Trading Resumption: Trading on a split-adjusted basis commences on November 14, 2016, on the NASDAQ Capital Market under the symbol "GALE".
- CUSIP Change: The new CUSIP number is 363256504.
- Fractional Shares: No fractional shares will be issued; holders entitled to fractions will receive a cash payment based on the pro-rata value of the closing market price for the five days preceding the effective date.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operational outlook, or specific risk factors beyond the mechanics of the stock split. The primary contingency noted is the cash payment mechanism for fractional shares.
Investor Verification Checklist
- Verify the new CUSIP number (363256504) with your brokerage to ensure proper account updates.
- Confirm the record date of November 11, 2016, for eligibility for the reverse split.
- Review the cash payment calculation method for fractional shares if holding a number of shares not divisible by 20.
- Monitor trading resumption on November 14, 2016, under the adjusted share count.